Noiembrie 2021: Primul studiu clinic al terapiei celulare cu receptorul antigen himeric T (CAR-T) de generație următoare din Coreea de Sud, care este conceput pentru a ocoli semnalele punctelor de control imun, a început recent.
Institutul Avansat de Știință și Tehnologie din Coreea (KAIST) a anunțat miercuri că un studiu clinic de fază 1b al terapiei sale cu celule CAR-T se desfășoară în prezent la Centrul Medical Samsung din Seul. Studiul se desfășoară pe 10 pacienți coreeni care au limfom difuz cu celule B mari recidivat și refractar. Drepturile de marketing pentru conductă au fost transferate de la universitate către compania Curocell, care a fost co-fondată de profesorul Kim Chan-hyuk. Curocell este responsabil de programul de dezvoltare clinică a revoluționarului imunoterapia.
In addition, a Phase 2 studiu clinic involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for receptor antigenic himeric T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Poate vă place să citiți: Terapia cu celule T CAR în Coreea
Concluziile studiului au fost prezentate într-un articol care a fost publicat online în numărul din octombrie al revistei Molecular Therapy.
